New Melanoma Metastasis Risk Prediction Tool Debuts
Source: Dermatology Times, February 2024
The test may help patients with melanoma safely avoid a sentinel lymph node biopsy.
Quest Diagnostics on Tuesday announced a new tool available to dermatologists for making treatment decisions for patients with melanoma.
The gene expression test, MelaNodal Predict, is based on technology developed by the oncology biotechnology company SkylineDx and researchers at Mayo Clinic.